“…In this context, the surgical management strategies of the RLN have undergone considerable change in the past; with lymphatic mapping and sentinel lymph node (SLN) identification being the most relevant contribution (Cabanas, 1977;Wong et al, 1991;Morton et al, 1992). On the basis of the concept that the regional lymphatics serve as a barrier, temporarily trapping the orderly tumour spread from the primary site to more distant locations, it was proposed that the histopathological status of the SLN would accurately predict melanoma metastases (Reintgen et al, 1994;Thompson et al, 1995). Today, SNB is the most important staging tool, because the status of the SLN represents the most important prognostic factor for recurrence and survival for melanoma patients and identifies patients who might benefit from further therapy, such as completion lymph node dissection (CLND) and adjuvant interferon therapy (Morton et al, 1999;Balch et al, 2001;Hafner et al, 2004;Eggermont et al, 2007).…”